- Home
- EWTX vs AIN Comparison
EWTX vs AIN Comparison
Compare EWTX & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- AIN
- Stock Information
- Founded
- EWTX 2017
- AIN 1895
- Country
- EWTX United States
- AIN United States
- Employees
- EWTX N/A
- AIN N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- AIN Textiles
- Sector
- EWTX Health Care
- AIN Consumer Discretionary
- Exchange
- EWTX Nasdaq
- AIN Nasdaq
- Market Cap
- EWTX 1.6B
- AIN 1.9B
- IPO Year
- EWTX 2021
- AIN 1987
- Fundamental
- Price
- EWTX $14.95
- AIN $55.75
- Analyst Decision
- EWTX Buy
- AIN Hold
- Analyst Count
- EWTX 10
- AIN 5
- Target Price
- EWTX $37.90
- AIN $71.40
- AVG Volume (30 Days)
- EWTX 957.0K
- AIN 297.1K
- Earning Date
- EWTX 11-06-2025
- AIN 10-29-2025
- Dividend Yield
- EWTX N/A
- AIN 1.94%
- EPS Growth
- EWTX N/A
- AIN N/A
- EPS
- EWTX N/A
- AIN 2.01
- Revenue
- EWTX N/A
- AIN $1,185,464,000.00
- Revenue This Year
- EWTX N/A
- AIN N/A
- Revenue Next Year
- EWTX N/A
- AIN $4.19
- P/E Ratio
- EWTX N/A
- AIN $27.63
- Revenue Growth
- EWTX N/A
- AIN N/A
- 52 Week Low
- EWTX $10.60
- AIN $50.60
- 52 Week High
- EWTX $38.12
- AIN $88.13
- Technical
- Relative Strength Index (RSI)
- EWTX 49.70
- AIN 43.14
- Support Level
- EWTX $14.85
- AIN $52.14
- Resistance Level
- EWTX $15.84
- AIN $54.08
- Average True Range (ATR)
- EWTX 1.08
- AIN 1.44
- MACD
- EWTX -0.06
- AIN 0.35
- Stochastic Oscillator
- EWTX 31.42
- AIN 63.94
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.